Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.
Introducing Anatara’s technology
Bromelain is a mixture of proteases extracted from pineapple stems. Specific proteases within Bromelain have anti-attachment, anti-secretory and anti-inflammatory activity. Collectively, these proteases provide a broad spectrum of activity as they not only prevent the diarrhoea-causing organism from attaching to the small intestine in the first place, but they also block inflammation and the secretory action of toxins, the underlying cause of diarrhoea. Anatara is developing proprietary formulations of bromelain for the prevention and treatment of gastrointestinal diseases in animals and humans.
Anatara’s lead product, Detach®, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour).
Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition. Increasing survivability and providing health benefits to pre-weaning piglets has been at the core of the development of Detach® since the Company was listed in 2014.
In October last year, Anatara announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) had registered Detach® with the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.
Anatara is evaluating commercialisation opportunities for Detach® including options for launch of the APVMA approved product in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and, global or regional licensing of Detach®.
Our Animal Applications page provides further information on our Detach® development plans.
Anatara is developing proprietary bromelain formulations for gastrointestinal health.
Introducing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted dietary supplement
Anatara’s GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
Our lead product is being positioned as an adjunct to existing therapies, and it will not be replacing current prescription medications. Over the last 20 years the use of dietary supplements as adjuncts to prescription drugs has increased significantly.
Our Human Applications page provides further information on our human development plans.
Anatara’s team and opportunity
Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health in humans.